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Abstract
Background Critically ill pediatric patients are considered at high risk for medication errors.
Although much research focuses on the actual errors, equally important are medication errors
that, although intercepted, carried the potential for an adverse drug event. The aim of this study
was to determine the occurrence of prescribing errors and potential adverse drug events (pADEs)
in a local pediatric intensive and critical care unit (PICU) in Hong Kong. Our secondary
objective was to determine the type of error, nature of medication involved and the time of error
occurrence.
Methods We conducted a prospective observational chart review among patients in a pediatric
intensive and high dependency unit between January 16, 2015 and April 20, 2015. Medical
charts for each patient were reviewed for the occurrence of a prescribing error or pADE. Each
pADE was assessed for the type of error, the classification of agent involved, clinical severity of
the error, and the time the error occurred.
Results Forty-one patients with a mean age of 3.2 years were included in our study. Of these
patients, 19 (46.3%) experienced at least one pADE. We identified 131 pADEs, 129 of which
were prescribing errors conferring a rate of 6.8 errors per affected patient or 3.1 errors per patient
admitted to the PICU. The most common error found in the study was incorrect dose calculation
(48.1%), with intravenous fluids (41.7%), cardiovascular agents (15.0%), and anti-infectives
(12.5%) the most common agents involved with an error. The majority of the pADEs in our
study were either clinically serious (33.1%) or significant (44.9%) in nature. Nearly one in every
four errors required monitoring and/or intervention to prevent harm, and almost all (96.9%) of
the prescribing errors were intercepted before reaching the patient.
Conclusion This study highlights incorrect dose calculation as the most common prescribing
error in a pediatric critical care setting. Intravenous fluids, cardiovascular agents, and antiinfectives were the classes of medication most commonly involved with a pADE. Due to the
highrisk nature of medications used and the critical condition of these patients, more than threequarters of pADEs were considered to be clinically serious or significant in causing patient harm.

1 Introduction
Medication errors are preventable events that may cause or lead to inappropriate medication use
or patient harm while the medication is in the control of the healthcare professional, patient, or
consumer [1]. Over the past two decades, preventing medication errors have been a major
healthcare priority. These errors pose a threat for serious harm and fatality to patients despite a
large number occurring without any harm or physical injury [2, 3]. Despite this, medication- or
therapy-related incidences are found to be the most common type of safety incidents reported
among pediatric intensive care patients, accounting for up to 40% of all safety incidents reported
in this setting [3].
Medication errors may result in either an adverse drug event (ADE) or a potential adverse drug
event (pADE). Adverse drug events, as defined by the Institute of Medicine (IOM), refer to
injuries or patient harm resulting from the use of a drug [4]. Errors that occurred but were
intercepted and did not result in patient harm are referred to as near miss incidents or pADEs [5].
pADEs are medication errors with the potential for injury but in which no injury occurred due to
either chance or an intervention [5–8]. Although not all ADEs (such as idiopathic allergic
reactions) occur due to a medication error, emphasis is often placed on medication errors due to
their preventable nature.
Information regarding medication errors among the pediatric population, although limited, points
towards a higher occurrence, with pediatric patients exposed to a three-times-higher rate of
pADE [8]. Kaushal et al. also reported prescribing errors among pediatric inpatients to be
significantly high with 74% of medication errors occurring during the physician ordering process
[8]. Within the pediatric intensive care unit, prescribing error rates range from 11.11 to 78.1%
depending on the type of critical care unit and whether orders were electronic or handwritten [2,
9–11]. Dosing errors in particular contribute to this increased risk for adverse drug events among
the pediatric population [12]. Such errors result due to the individualized weight-based dose
calculations necessary in this patient population, thereby resulting in a wide range of acceptable
doses prescribed. Other factors precipitating a higher risk for errors include the lack of
appropriate formulations and unfamiliarity with caring for pediatric patients [13].
Critically ill pediatric patients\2 years of age are at an even higher risk for adverse events [14].
The complexity of their condition, the likelihood of being on a large number of medications, and
the high-risk nature of the medications used in this setting contribute to the higher risk for
clinically severe to potentially lethal medication errors [15].These patients also have limited
physiologic reserves to compensate for or accommodate such errors, further increasing their risk
for harm [8]. In addition, the majority of the medications used within this subgroup of pediatric
patients are used off label with no FDA approval for use or with approval among limited age
groups [16]. Many of these medications are on the Institute of Safe Medical Practice’s (ISMP’s)
list of high-risk medications due to their ability to increase risk for patient harm when used in
incorrectly [17]. Given the multiple factors involved and the individualized dose calculation
made during the prescribing process, prescribing errors are often recognized as a leading cause
of medication error among this group of patients [14].

The primary objective of the study is to determine the occurrence and nature of prescribing
errors and pADEs among critically ill pediatric patients in a Hong Kong hospital. Although we
expect some similarities in our results, some potential differences between our findings and those
from other countries might be present due to differences in error reporting culture, use of a
paper-based medication ordering system, workflow logistics, and other factors that may translate
to differences in the occurrence, type, and nature of prescribing errors in a pediatric intensive
care unit (ICU).

2 Methods
2.1 Study Design, Study Site and Patient Population
This is a prospective observational study to identify prescribing errors among patients admitted
to the pediatric intensive care and high dependency unit (PICU) of a regional 870-bed acute care
public hospital in Hong Kong. The study was conducted from January 16, 2015 to April 20,
2015. Patients ≥29 days old and on at least one active medication were included in the study for
the duration of their PICU stay. The institution is accredited by the Australian Council of
Healthcare Standards (ACHS) and serves as the major referral center for hospitals in the New
Territories East Cluster. The study unit is a tertiary level pediatric ICU equipped with respiratory
support, various modes of ventilation and circulatory support in renal replacement therapy. The
unit consists of three pediatric high dependency beds and five acute intensive care beds. Patients
admitted to the acute intensive care unit have a patient to nurse ratio of approximately 1:4.6,
while those in the high dependency unit have a ratio of approximately 1:2–1:2.5. A two-tier
system for physicians is adopted during the daytime ward rounds with one first call physician
and a more senior team head. The level of experience for the first call physician varies from a
first year medical offer to a specialist with up to 6 years of experience, while physician team
heads have more than 10 years of experience. All prescription orders are hand-written on a
paper-based medication chart. Orders are then manually transcribed onto a Medication
Administration Record (MAR) form, which is sent electronically to the main pharmacy for
preparation and dispensing. A clinical pharmacist is available on weekdays and reviews all
orders written on the patient’s chart for errors and drug-related problems.

2.2 Definition of Potential Adverse Drug Events and Identification of Errors
We defined prescribing errors based on the IOM definition, wherein the error occurred during
the order writing or transcribing phase. All orders, pharmacological (such as medications) and
non-pharmacological (such as nutritional supplements or milk formulas), written by physicians
were included in our review. The research team, consisting of a PICU senior physician team
head, a clinical pharmacist, and two pharmacy students, reviewed all written orders for
prescribing errors. The team evaluated each error to determine whether the correction or
discrepancies from the original order was intentional (i.e., based on the recommendations of a
consultant physician or pharmacist) or not. Intentional corrections were not considered to be

errors and were subsequently excluded from further data analysis. Prescribing errors that were
true errors were assessed for the type of error, the classification of medication or agent involved,
and the time of day the error occurred. Errors were categorized as wrong rate of administration,
wrong drug, wrong dose, wrong unit, wrong dosage interval (frequency), wrong dosage form,
wrong body weight, wrong diluent, wrong strength (or strength unavailable), and wrong route. A
modified version of the World Health’s Organization’s (WHO’s) Anatomical Therapeutic
Chemical (ATC) classification was used to categorize the medications involved [18].
Each prescribing error was initially considered a potential ADE as the error had the possibility of
resulting in a negative outcome [19]. Those corrected before reaching the patient were
considered as intercepted pADEs. A non-intercepted pADE referred to a prescribing error that
was not corrected, reached the patient, but did not result in patient harm [9]. Intercepted
prescribing errors were identified based on the presence of a correction or alteration in the
original handwritten order on the patient’s medical record or medication administration record.
Non-intercepted prescribing errors were identified based on discrepancies between clinical notes
and order regimen in the absence of any corrections. All non-intercepted pADEs were evaluated
for the occurrence of patient harm. Errors that were not intercepted or corrected, reached the
patient, and resulted in patient harm were considered actual ADEs. Drug-related problems
identified by clinical pharmacists were also included as pADEs. The National Coordination
Council for Medication Error Reporting and Prevention (NCCMERP) index was used to
categorize medication errors while the clinical severity of the error was assessed by adopting the
rating based on Overhage and Lukes (Table 1) [1, 20].

2.3 Data collection and Data Analysis
Medical charts of all patients eligible for inclusion were reviewed twice weekly for any
prescribing errors during their PICU admission. Data collection times were scheduled on
Monday and Thursday to consolidate the collection times and minimize interference with
workflow. Demographic and clinical data including gender, age, and diagnosis were collected
along with details of the prescribing errors such as time the order was written, name of the
medication, along with its dose and frequency of administration. The total number of concurrent
medications each patient had at the time of the occurrence of the error was also noted.
Descriptive statistics were used for baseline characteristics and primary and secondary outcomes,
and were analyzed using Microsoft Excel version 2010. Statistical analyses were conducted
using Statistical Package for Social Sciences version 23.0 (SPSS, Inc., Chicago, USA). The
study obtained approval by the institution’s investigational review committee.

3 Results
3.1 Patient Demographics and Characteristics
Forty-two patients were admitted to the PICU during our study. One patient did not meet the
minimum age criteria of 29 days and was excluded from the study. The remaining 41 patients

included in our study had a mean age of 3.2 years (interquartile range [IQR] 2.3–5). Admission
into the PICU was most frequently due to diseases in the respiratory system. Patients were also
noted to have an average of 5.3 concurrent medications during the time of medication chart
review. Characteristics of the study population are presented in Table 2.

3.2 Prescribing Errors and Potential Adverse Drug Events
We reviewed 217 medication orders suspected to be prescribing errors, with 86 considered by
the investigational team to be error free and excluded from subsequent analysis. The remaining
131 (60.4%) medication orders were determined to be pADEs. Two were the use of an
unnecessary drug and were categorized as drug-related problems. The remaining 129 (96.9%)
were category B errors or intercepted pADEs. We classified these as prescribing errors. This
corresponded to19 (46.3%) patients having a minimum of one pADE. The number of prescribing
errors found resulted in a rate of 6.8 errors per patient affected or 3.1 errors per patient admitted
to the study unit. Of the 129 prescribing errors, two intercepted errors involved an incorrect body
weight documented. We classified both as a wrong dose prescribing error; however, they were
excluded from analysis for classification of medication and clinical severity as it was difficult to
determine which of the medications could have been involved, if any. This resulted in 127
intercepted prescribing errors included in our medication class and clinical severity analysis
(Table 3).

3.3 Clinical Significance of Potential Adverse Events, Type of Error and Nature of
Medication Involved
Over three quarters (78%) of the 127 errors were found to be at least clinically significant or
clinically serious and 20.5% were found to be of minor clinical severity. Two pADEs (1.6%)
were classified by investigators as potentially lethal. The first potentially lethal pADE involved
an order for fentanyl while the second involved noradrenaline. Nearly one of every four pADEs
required monitoring and/ or intervention to prevent harm (Table 4).
We reviewed all orders prescribed to patients, both pharmacological and non-pharmacological,
and found intravenous fluid solutions were involved in 50 (41.7%) of the pADEs, representing
the class of medications with the largest number of prescribing errors. Cardiovascular agents,
anti-infectives, and analgesics followed with 18 (15.0%), 15 (12.7%), and 12 (10.0%) pADEs
associated with each class, respectively. Errors of various clinical severity occurred across all
medication classes and non-pharmacological products. Of the 50 pADEs due to intravenous fluid
solutions, 14 (28%) and 25 (50%) were potentially severe and significant pADEs. Further
subgroup analysis found approximately three quarters of errors from the aforementioned class of
medication were either clinically severe or serious (Fig. 1). The most frequent type of error
involved a wrong dose, which occurred among 62 (48.1%) of the pADEs noted. A wrong rate of
administration, wrong drug, and wrong dosing interval were subsequently the most common
prescribing errors with 24 (18.6%), 11 (8.5%), and 10 (7.8%) errors, respectively. Among the

pADEs assessed, a higher number of such prescribing errors occurred in the early morning to
noon period.
4 Discussion
Our study sought to determine the incidence of prescribing errors and corresponding actual or
potential ADEs in a pediatric critical care unit. We adopted the term ‘pADE’ rather than ‘near
miss’, however both terms have been used interchangeably in other clinical risk management
studies [9]. We focused on this patient group due to the increased risk for medication errors, up
to 60%, among patients <2 years of age in the pediatric ICU [15]. Although patients in our study
with at least one pADE were younger (2.1 vs 4.2 years), previous studies indicate no correlation
between age and the occurrence of prescribing errors [3, 14, 19].
Prescribing errors have an alarmingly high incidence with up to 79% of pADEs reported during
the prescribing process [8]. Our study identified that 46.3% of patients admitted to the PICU
experienced at least one pADE. This was similar to results from a cohort of Swiss patients,
where 42.48% of patients in the PICU had at least one prescribing error [14]. Other studies show
a larger range with one study in New Zealand reporting the frequency of pADEs to be 26.4%
among their pediatric surgical wards while investigators in the US found pADEs comprised 83%
of all medication errors [7, 21]. Although numerous studies exist regarding the rate of errors,
most of the reported pADEs among pediatric patients were based on medication errors rather
than prescribing errors specifically [7, 21].
Almost all (96.9%) of the prescribing errors were intercepted before reaching the patient.
However, our results should not underestimate the potential risk in patient safety. In a study
conducted among pediatric ICU clinicians, the five most commonly acknowledged high-alert
medications used among critically ill pediatric patients were also included in the ISMP list [22].
Given the heavy use of such medications in our study population, more than three quarters
(77.1%) of all pADEs were clinically significant with most of them being severe or serious
pADEs. Potentially lethal errors were also reported most frequently among patients admitted to
the pediatric ICU (0.29 vs 0.09; p<0.001), further suggesting the significance of such errors [15].
In our study, two errors were found to be of such grave severity. The first error pertained to the
use of fentanyl in a 17-month-old male infant with respiratory failure where the original order
was written as per minute rather than per hour. The second error involved noradrenaline in a 5year-old male child with multiple comorbidities. The initial order was written in mg/kg rather
than μg/kg.
Intravenous solutions, anti-infectives, and cardiovascular agents were the medication classes
found to have the most pADEs, a finding similarly observed among pediatric inpatients in other
countries [21]. Similar studies conducted to determine errors in the pediatric ICU reported that
antiinfective agents, intravenous medications, sedatives, cardiovascular agents, and analgesics
were the medications most likely to be associated with an error, with one study reporting that up
to 50% of prescribing errors were associated with antihypertensives and antimycotics [8, 14, 21].
Incorrect dose calculations was the most common type of error observed, a finding universally
consistent across all studies [8, 15, 22–26]. The National Patient Safety Agency in the UK

highlighted the three most common medication incidence types: wrong or unclear dose, strength
or frequency; omitted or missed dose; and wrong drug [26]. One study in Hong Kong also
reported consistent findings with 39.5% of problems identified to be drug- or dose-related [27].
The multi-step process involved in calculating a dose is one of the vulnerable areas for
prescribing errors to occur. Frequent dose adjustments needed to optimize fluids and electrolytes
compound this risk, as dose recalculations are required to achieve the delicate balance between
sufficient versus over-hydration or over-correction resulting from the frequent fluctuations in
their critical state.
We noted two prescribing errors where no interception was indicated. One occurred over a
weekend and was corrected on Monday by the clinical pharmacist assigned to the unit. We were
unable to determine if either of the patients were administered the erroneous order or whether
harm incurred. We speculate that one of the following situations occurred: the patient was
administered the drug but did not experience any harm, or the error was identified and corrected
before reaching the patient but was not documented in the patient’s chart. Considering the
potential outcome of such errors, we predict the latter scenario occurred. Our study also noted
that prescribing errors occurred in the morning, coinciding with the time for patient care rounds.
This was similar to a previous study where 73% of all errors occurred during the daytime
(between 07:00 and 19:00) [9].
Risk management strategies such as failure mode and effects analysis (FMEA) offer a systematic
approach to prevent the occurrence of medication errors [28, 29]. These strategies have proven to
be effective in reducing the risk for medication errors among various pediatric patient
populations. Lago et al. reported a reduction of 60% among high-risk failure modes in pediatric
prescribing and administration errors with the use of FMEA [30]. At our study institution, all
medical or medication incidents are reported through the hospital’s Acute Incident Reporting
System (AIRS) and forwarded to the hospital’s Quality and Risk Department for appropriate
action. Root cause analyses (RCAs) and FMEAs are both conducted for all incidences. An
incident-specific committee discusses the error and interviews medical, nursing and relevant
staff. The risk-management committee within the Department of Pediatrics of the study
institution also assists in the evaluation and action of all reported incidents among the pediatric
wards. This most likely contributed to the high number of intercepted prescribing errors.
Specific interventions recognized to reduce medication errors in the pediatric ICU and pediatric
population in general include computerized physician order entry (CPOE) with or without
clinical decision support, standardized intravenous systems, educational methods, protocols and
guidelines, pharmacist involvement, and clinical decision support systems [2, 8, 10, 31–33].
Active participation and availability of a unit-based clinical pharmacist during and outside of
physician rounds have shown to decrease the number of medication errors in the pediatric
population [10, 14, 34]. A reduction in prescribing error rates, from 78.1 to 35.2% (p < 0.001),
was observed when pharmacists provided interventions such as the provision of drug use
assistance during point of care, structured combined order and administration charts, educational
talks, and feedback for resident physicians [9, 11]. Given the limited number of clinical
pharmacists in our study institution, clinical pharmacy services are only available from 9 a.m. to

5 p.m., Mondays through Fridays excluding public holidays, and the assigned clinical pharmacist
is responsible for patients in the PICU, the neonatal ICU (NICU), and the Special Baby Care
Unit (SBCU). With the large number of patients under their care, pediatric pharmacists are often
absent during patient rounds. This model of service was adopted to accommodate the high
patient-to-pharmacist ratio among public hospitals in Hong Kong. As a result, gaps in patient
care continue to exist and the burden of correcting errors before they reach the patient may be
unequally distributed among the healthcare team. Although our study shows the absence of
patients being harmed, solely preventing errors may not necessarily translate to the most
effective and ideal care for the patient.
Numerous interventions also exist specific to dosing errors. These include providing dosing
assistance, communication or educational interventions, education of physicians, and zero
tolerance prescribing [11, 33]. Additional interventions such as having a standardized
prescription information source, pocket tables with dosing guidelines, updated prescription
protocols, and education programs significantly decreased prescribing error rate in a PICU [2].
The National Health Service (NHS) in the UK has highlighted the incorporation of computerized
software to perform calculations, double checking procedures, electronic prescribing systems,
clinical pharmacist activity, and utilization of smart pumps [35]. Standardization of continuous
infusions or intravenous drips may also simplify the order process of fluids and electrolytes,
thereby reducing dosing errors among these agents [36].
Along with the findings presented, our study has some limitations. The absence of a control
group and the limited size of the study population prevented us from identifying and assessing
risk factors for prescribing errors and pADEs. Secondly, our study was an observational study.
These results do not reflect methods to address or minimize prescribing errors. Furthermore,
although the researchers adopted the NCCMERP along with a clinical severity assessment tool,
the investigators’ clinical judgment was taken into consideration when assigning the clinical
severity of the errors. The patients’ clinical condition and concurrent medications at the time of
the errors may have led to a potential bias in severity assessment. We acknowledge the
possibility that errors may have been intercepted after the medication had been administered,
thereby under-representing the number of actual or potential ADEs. Finally, our results do not
translate to errors during drug dispensing, preparation, or administration.

5 Conclusion
This study provides valuable insight into the occurrence and nature of prescribing errors and
potential ADEs among critically ill pediatric patients in Hong Kong. Our study shows the
consistency of incorrect dose calculations as one of the leading causes of prescribing errors. Our
results also highlight specific classes of medications such as intravenous fluids, cardiovascular
agents, and anti-infectives most likely associated with an error. Such results may be applicable to
other pediatric populations as well, in particular those requiring continuous intravenous infusion,
fluids, and electrolyte supplementation, or requiring frequent adjustments and dose
recalculations. Although the current system was able to prevent most of the prescribing errors,

the study emphasizes the high risk for harm based on the significant clinical severity in the
majority of these errors should they have gone uncorrected. Future considerations such as
broadening clinical pharmacist coverage, and the use of other interventions such as computerized
physician order entry systems and standardized infusion regimens may contribute to not only
ensuring medication safety but also to improving standard of care among critically ill pediatric
patients.
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